A practical reference on albumin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-10 and is reviewed periodically as new material appears.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Docetaxel is a cytotoxic chemotherapeutic agent. As with all chemotherapy, adverse effects are common, and many side effects have been documented. Because docetaxel is a cell-cycle-specific agent, it is cytotoxic to all dividing cells in the body. This includes tumour cells as well as hair follicles, bone marrow and other germ cells. For this reason, common chemotherapy side effects such as hair loss occur; sometimes this can be permanent. North west France are conducting a survey to establish exactly how many people are affected in this way. Independent studies show it could be as high as 6.3%, which puts it in the 'common and frequent' classification. Haematological adverse effects include neutropenia (95.5%), anaemia (90.4%), febrile neutropenia (11.0%) and thrombocytopenia (8.0%). Deaths due to toxicity accounted for 1.7% of the 2045 patients, and incidence was increased (9.8%) in patients with elevated baseline liver function tests (liver dysfunction). The use of docetaxel during chemotherapy, especially when given weekly, may lead to complications with the lacrimal drainage system. The mechanism for this problem seems to be secretion of docetaxel by the lacrimal gland which can then cause stenosis, or narrowing, of the punctum and canalicular outflow system. In most cases the primary symptoms is epiphora or tearing. When treated early most patients can avoid the need for surgery, but some cases the only cure is a conjunctivodacryocystorhinostomy in which a glass tube is placed to bypass the tear duct. Taxane-induced pneumotoxicity is rare.
Miller (1992), professor of law at the University of Iowa Matthew Shum (1992), professor of economics at California Institute of Technology Victor Fleischer (1993), professor of law at University of California, Irvine Valerie Purdie Greenaway (1993), professor of psychology and first African-American to receive tenure in the sciences at Columbia University Michelle Hartman (1993), professor of Arabic and francophone literature at McGill University Soyoung Lee (1993), chief curator of the Harvard Art Museums Seth Rockman (1993), professor at Brown University, co-recipient of the 2010 Merle Curti Award David Rosen (1993), professor at Trinity College, Connecticut, recipient of the 2013 James Russell Lowell Prize David Eisenbach (1994), historian on media and politics; narrator, 10 Things You Don't Know About François Furstenberg (1994), historian at Johns Hopkins University Katerina Harvati (1994), professor of paleoanthropology at the University of Tübingen, identified the earliest known sample of the remains of modern humans outside Africa Ayanna Thompson (1994), professor of English at Arizona State University, president of the Shakespeare Association of America David H.
Logical Observation Identifiers Names and Codes (LOINC) is a database and universal standard for identifying medical laboratory observations. First developed in 1994, it was created and is maintained by the Regenstrief Institute, a US nonprofit medical research organization. LOINC was created in response to the demand for an electronic clinical care and management database and is publicly available at no cost. It is endorsed by the American Clinical Laboratory Association. Since its inception, the database has expanded to include not just medical laboratory code names but also nursing diagnosis, nursing interventions, outcomes classification, and patient care data sets.
=== Discovery of biomolecules through metagenomics === The advances in modern sequencing technologies in the late 1990s allowed scientists to investigate DNA of communities of organisms in their natural environments ("eDNA"), without culturing individual species in the lab. This metagenomic approach enabled scientists to study a wide selection of organisms that were previously not characterized due in part to an incompetent growth condition. Sources of eDNA include soils, ocean, subsurface, hot springs, hydrothermal vents, polar ice caps, hypersaline habitats, and extreme pH environments. Of the many applications of metagenomics, researchers such as Jo Handelsman, Jon Clardy, and Robert M. Goodman, explored metagenomic approaches toward the discovery of biologically active molecules such as antibiotics.
Another formation with Tyrannosaurus remains is the Lance Formation of Wyoming. This has been interpreted as a bayou environment similar to today's Gulf Coast. The fauna was very similar to Hell Creek, but with Struthiomimus replacing its relative Ornithomimus. The small ceratopsian Leptoceratops also lived in the area. In its southern range, specifically based on remains discovered from the North Horn Formation of Utah, Tyrannosaurus rex lived alongside the titanosaur Utetitan, the ceratopsid Torosaurus and the indeterminate troodontids and hadrosaurids. Tyrannosaurus mcraeensis from the McRae Group of New Mexico coexisted with the ceratopsid Sierraceratops and possibly the titanosaur Alamosaurus. Potential remains identified as cf. Tyrannosaurus have also been discovered from the Javelina Formation of Texas, where the remains of the titanosaur (either Alamosaurus or Utetitan), the ceratopsid Bravoceratops, the pterosaurs Quetzalcoatlus and Wellnhopterus, and possible species of troodontids and hadrosaurids are found. Its southern range is thought to have been dominated by semi-arid inland plains, following the probable retreat of the Western Interior Seaway as global sea levels fell. Tyrannosaurus may have also inhabited Mexico's Lomas Coloradas Formation in Sonora. Though skeletal evidence is lacking, six shed and broken teeth from the fossil bed have been thoroughly compared with other theropod genera and appear to be identical to those of Tyrannosaurus. If true, the evidence indicates the range of Tyrannosaurus was possibly more extensive than previously believed.
Sources: en.wikipedia.org
Out-patient service In-patient services Maternity service 24 hours emergency services X-Ray, ECG Clinical Laboratory Ultrasound Facility Treatment for snake bites Immunization Ambulance service The following specialities and consultations are available:
The Provisional Act on Lawyers of the People's Republic of China went into effect, easing the requirements for a Chinese citizen to represent a client in a trial court or an appellate court. In the Netherlands, a merger took place between the two largest trade unions for transportation workers, the Nederlandse Bond van Vervoerspersoneel (NBV) of 49,000 members, and the Katholieke Bond van Vervoerspersoneel (KBV) of 20,000. The NBV-KBV combination became the Vervoersbond, or "VB". Nippon Kokan (based in the Tokyo suburb of Kawasaki defeated Tokyo's Yomiuri FC soccer football team, 2 to 0, to win the Emperor's Cup Malaysia change it's time zone to UTC:8:00 from its former time zone UTC:7:30 Died: Victor Buono, 43, American character actor on film and television, was found dead in his home.
=== Pharmacological treatment === Since the early 2020s, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become an increasingly important component of obesity treatment in Brazil. The Brazilian Health Regulatory Agency approved liraglutide for weight management in adolescents in August 2020, followed by the approval of semaglutide for expanded use in September 2023. These approvals introduced the first GLP-1 receptor agonists specifically indicated for obesity treatment in Brazil. Subsequent years saw rapid growth in the use of semaglutide and other GLP-1-based therapies, concentrated predominantly in higher-income regions. The expansion was accompanied by increasing regulatory attention regarding off-label use and counterfeit products. Brazilian clinical guidelines recommend GLP-1 receptor agonists as part of evidence-based obesity management in selected patients. A 2025 position statement issued jointly by five Brazilian medical societies reinforced the role of GLP-1 receptor agonists — including liraglutide, semaglutide, and tirzepatide - in the pharmacological management of obesity and prevention of cardiovascular complications. Internationally, semaglutide has been recognised as a significant development in obesity pharmacotherapy, with clinical trials demonstrating weight reductions of approximately 15–17% of baseline body weight in adults without type 2 diabetes.
=== Interaction with lipid membranes === Experimental evidence has been collected on the interaction of alpha-synuclein with membrane and its involvement with membrane composition and turnover. Yeast genome screening has found that several genes that deal with lipid metabolism and mitochondrial fusion play a role in alpha-synuclein toxicity. Conversely, alpha-synuclein expression levels can affect the viscosity and the relative amount of fatty acids in the lipid bilayer. Alpha-synuclein is known to directly bind to lipid membranes, associating with the negatively charged surfaces of phospholipids. Alpha-synuclein forms an extended helical structure on small unilamellar vesicles. A preferential binding to small vesicles has been found. The binding of alpha-synuclein to lipid membranes has complex effects on the latter, altering the bilayer structure and leading to the formation of small vesicles. Alpha-synuclein has been shown to bend membranes of negatively charged phospholipid vesicles and form tubules from large lipid vesicles. Using cryo-EM it was shown that these are micellar tubes of ~5-6 nm diameter. Alpha-synuclein has also been shown to form lipid disc-like particles similar to apolipoproteins. EPR studies have shown that the structure of alpha synuclein is dependent on the binding surface. The protein adopts a broken-helical conformation on lipoprotein particles while it forms an extended helical structure on lipid vesicles and membrane tubes. Studies have also suggested a possible antioxidant activity of alpha-synuclein in the membrane.
17 August – SNP MSP John Mason is stripped of the party whip after a Twitter post in which he said that Israel's actions in Gaza did not amount to "genocide", something a party spokesperson describes as "completely unacceptable". 19 August – A rocket being developed by Rocket Factory Augsburg, a German company hoping to launch the UK's first space flight, explodes during a launch test at the Shetland Space Centre. The Scottish Government announces it will hold no further talks with Israeli ambassadors until there is "real progress" in resolving the Gaza conflict. Christina McKelvie, the Scottish Government's Minister for Drugs and Alcohol Policy, announces she will step back from the role while receiving treatment for secondary breast cancer. Her duties will be assumed by fellow ministers Neil Gray and Jenni Minto. 20 August – Data released by National Records of Scotland shows a 12% increase in the number of drug related deaths in Scotland during 2023, with 1,172 deaths that year, an increase of 121 from 2022. Transport Scotland announces that its pilot scheme of subsidising peak-time ScotRail fairs will end in September, having not achieved the goal of encouraging more people to travel by train rather than by road. 21 August – Aberdeen City Council announces that several hundred properties in Aberdeen affected by Reinforced Autoclaved Aerated Concrete are to be demolished and rebuilt at a cost of £150m. 22 August – Edinburgh City Council votes to introduce a tourist tax that it hopes will raise around £50m a year.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.